Literature DB >> 33525645

Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals.

Junko Fukuda1, Kenji Ikezawa2, Miho Nakao1, Suetsumi Okagaki1, Reiko Ashida1, Tatsuya Ioka1, Ryoji Takada2, Takuo Yamai2, Nobuyasu Fukutake2, Hiroyuki Uehara2, Shigenori Nagata3, Hidenori Takahashi4, Takahiro Tabuchi5, Sachiko Tanaka1, Kazuyoshi Ohkawa2, Kazuhiro Katayama1,2.   

Abstract

Because pancreatic cancer has a dismal prognosis, a strategy for early diagnosis is required. This study aimed to identify predictive factors of neoplastic progression in patients at high risk for pancreatic cancer and examined the efficiency of surveillance using transabdominal special ultrasonography focusing on the pancreas (special pancreatic US). Patients with slight main pancreatic duct (MPD) dilatation (≥2.5 mm) and/or pancreatic cysts (≥5 mm) were enrolled in a prospective surveillance study with special pancreatic US in a Japanese cancer referral center. A total of 498 patients undergoing surveillance for ≥3 years were included. During the median follow-up of 5.9 years, neoplastic progression developed in 11 patients (2.2%), including 9 patients who underwent pancreatectomy. Eight patients (72.7%) were diagnosed with stage 0/I disease, with an overall survival duration of 8.8 years. Findings of both MPD dilatation and pancreatic cysts at initial surveillance, MPD growth (≥0.2 mm/year) and cyst growth (≥2 mm/year) during surveillance were identified as independent risk factors for neoplastic progression. In summary, surveillance with special pancreatic US for high-risk individuals contributed to earlier detection of neoplastic progression, leading to a favorable prognosis. During surveillance, attention should be paid to MPD growth as well as to cyst growth.

Entities:  

Keywords:  IPMN; MPD growth rate; early detection; pancreatic cancer; special pancreatic US

Year:  2021        PMID: 33525645      PMCID: PMC7865866          DOI: 10.3390/cancers13030502

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  30 in total

1.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

Authors:  Santhi Swaroop Vege; Barry Ziring; Rajeev Jain; Paul Moayyedi
Journal:  Gastroenterology       Date:  2015-04       Impact factor: 22.682

2.  Evaluating the ability to detect pancreatic lesions using a special ultrasonography examination focusing on the pancreas.

Authors:  Miho Nakao; Kazuhiro Katayama; Junko Fukuda; Suetsumi Okagaki; Kozo Misu; Sayako Miyazaki; Noritoshi Matsuno; Reiko Ashida; Tatsuya Ioka; Yuri Ito; Kazuyoshi Ohkawa
Journal:  Eur J Radiol       Date:  2017-03-22       Impact factor: 3.528

3.  Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.

Authors:  Marcia Irene Canto; Jose Alejandro Almario; Richard D Schulick; Charles J Yeo; Alison Klein; Amanda Blackford; Eun Ji Shin; Abanti Sanyal; Gayane Yenokyan; Anne Marie Lennon; Ihab R Kamel; Elliot K Fishman; Christopher Wolfgang; Matthew Weiss; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2018-05-24       Impact factor: 22.682

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions.

Authors:  Teppei Yoshioka; Minoru Shigekawa; Kenji Ikezawa; Takeshi Tamura; Katsuhiko Sato; Makiko Urabe; Hironari Sueyoshi; Takuo Yamai; Takahiro Suda; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Pancreas       Date:  2020-04       Impact factor: 3.327

6.  Observational study of the incidence of pancreatic and extrapancreatic malignancies during surveillance of patients with branch-duct intraductal papillary mucinous neoplasm.

Authors:  Giuseppe Malleo; Giovanni Marchegiani; Alex Borin; Paola Capelli; Federico Accordini; Giovanni Butturini; Paolo Pederzoli; Claudio Bassi; Roberto Salvia
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

7.  Clinicopathological aspects of small pancreatic cancer.

Authors:  Shinichi Egawa; Kazunori Takeda; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Seiki Matsuno
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 9.  Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis.

Authors:  Wei-Chih Liao; Yu-Kang Tu; Ming-Shiang Wu; Jaw-Town Lin; Hsiu-Po Wang; Kuo-Liong Chien
Journal:  BMJ       Date:  2015-01-02

Review 10.  Similarities and differences in guidelines for the management of pancreatic cysts.

Authors:  Gandhi Lanke; Jeffrey H Lee
Journal:  World J Gastroenterol       Date:  2020-03-21       Impact factor: 5.742

View more
  3 in total

1.  Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer.

Authors:  Kenji Ikezawa; Tomoya Ekawa; Shinichiro Hasegawa; Yugo Kai; Ryoji Takada; Takuo Yamai; Nobuyasu Fukutake; Hisataka Ogawa; Takashi Akazawa; Yu Mizote; Kumiko Tatsumi; Shigenori Nagata; Kei Asukai; Hidenori Takahashi; Kazuyoshi Ohkawa; Hideaki Tahara
Journal:  Endosc Int Open       Date:  2022-01-11

2.  Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.

Authors:  Takuo Yamai; Kenji Ikezawa; Erika Hiraga; Yasuharu Kawamoto; Takeru Hirao; Sena Higashi; Kazuma Daiku; Shingo Maeda; Yutaro Abe; Makiko Urabe; Yugo Kai; Ryoji Takada; Tasuku Nakabori; Nobuyasu Fukutake; Hiroyuki Uehara; Masashi Fujita; Kazuyoshi Ohkawa
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

3.  Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.

Authors:  Kenji Ikezawa; Ryosuke Kiyota; Ryoji Takada; Kazuma Daiku; Shingo Maeda; Toshihiro Imai; Yutaro Abe; Yugo Kai; Takuo Yamai; Nobuyasu Fukutake; Tasuku Nakabori; Reiko Ashida; Hiroyuki Uehara; Takahiro Tabuchi; Kazuhiro Katayama; Kazuyoshi Ohkawa
Journal:  JGH Open       Date:  2021-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.